Amunix Announces the Appointment of Healthcare Investment Banking Veteran Zeeshan Merchant as Chief Financial Officer and Trisha Millican to the Board of Directors
January 26, 2021 07:00 ET
|
Amunix Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent...
Immunophotonics Announces First Patient Treated in Clinical Study Evaluating IP-001 in Patients with Advanced Solid Tumors
November 10, 2020 01:08 ET
|
Immunophotonics, Inc.
ST. LOUIS and BERN, Switzerland, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. announces the first patient treated in the phase 1b/2a clinical trial examining IP-001 in thermally ablated...
L'inclusion du premier patient dans l'essai clinique de Phase 3 avec monalizumab déclenche un paiement de 50M$ d'AstraZeneca
October 23, 2020 01:00 ET
|
INNATE PHARMA
Ce paiement d’étape renforce la position de trésorerie d’Innate INTERLINK-1 est la première étude de Phase 3 étudiant une approche d’immunothérapie chez des patients présentant un cancer de la tête...
First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca
October 23, 2020 01:00 ET
|
INNATE PHARMA
Milestone payment further bolsters Innate’s cash position INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treated with a platinum-based therapy...
Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million
July 15, 2020 08:05 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with institutional investors providing for...
Amunix Appoints Anne Keane as Senior Vice President of Regulatory and Quality
May 27, 2020 07:00 ET
|
Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent...
Innate Pharma présente de nouvelles données d'efficacité pour monalizumab en combinaison avec cetuximab dans les cancers de la tête et du cou lors de congrès virtuel de l'ASCO20
May 14, 2020 01:00 ET
|
INNATE PHARMA
Dans l’expansion de cohorte (Phase II), un taux de réponse globale de 20% a été observé chez des patients précédemment traités par une immunothérapie anti-PD-(L)1 Ces données confirment les...
Innate Pharma to Present New Efficacy Data For Monalizumab in Combination With Cetuximab in Head And Neck cancer at The ASCO20 Virtual Scientific Progral
May 14, 2020 01:00 ET
|
INNATE PHARMA
Phase II expansion cohort of “IO-pretreated patients” demonstrates 20% overall response rate Data confirm previous preliminary efficacy data seen in this subpopulation Innate Pharma SA (Euronext...
Innate Pharma to Present New Efficacy Data for Monalizumab in Combination With Cetuximab in Head and Neck Cancer at the ASCO20 Virtual Scientific Program
May 14, 2020 01:00 ET
|
INNATE PHARMA
Phase II expansion cohort of “IO-pretreated patients” demonstrates 20% overall response rate Data confirm previous preliminary efficacy data seen in this subpopulation MARSEILLE, France,...
Cybrexa Therapeutics to Present at BIO Digital and Sachs 6th Annual Digital Immuno-Oncology Innovation Forum
May 07, 2020 11:27 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., May 07, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...